How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
agreement with CordenPharma for both the oral and subcutaneous (SC) formulations of its obesity drug. Viking Therapeutics is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and SC versions for treating obesity. Per the terms, CordenPharma will provide 100 million autoinjectors, 100 million vial and syringe products, and more than 1 billion oral VK2735 tablets annually through dedicated manufacturing lines. In addition, VKTX will retain an option to expand these capacities. In return, the company will make prepayments totaling $150 million over the next three years, which will be adjusted against future orders. This deal with CordenPharma reduces the supply chain risk on VKTX stock, which is a likely reason for this upside in stock price. Let's delve into the company's strengths and weaknesses to better analyze how to pl
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $104.00 price target on the stock.MarketBeat
- Why Viking Therapeutics Stock Popped Today [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $75.00 price target on the stock, down previously from $95.00.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its price target lowered by analysts at Morgan Stanley from $105.00 to $102.00. They now have an "overweight" rating on the stock.MarketBeat
VKTX
Earnings
- 4/23/25 - Miss
VKTX
Sec Filings
- 4/24/25 - Form 10-Q
- 4/23/25 - Form DEFA14A
- 4/23/25 - Form DEFR14A
- VKTX's page on the SEC website